AzTrials
AzTrials

Tumors of the Central Nervous SystemNCT05641636

Cardiovascular Disorders and Risk Factors in Childhood Cranial and Craniospinal Tumors Survivors

An observational study of Tumors of the Central Nervous System and Childhood Cancer Survivors, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of research is to study to adverse cardiovascular disorder and risks factors in childhood cranial and craniospinal tumors survivors. In this research the investigators investigate cardiological instrumental diagnostic, such as electrocardiography, echocardiography with the determination of global… Read more about this study

Who is it for?
Ages 16 to 40 yearsHealthy volunteers can take part
What is being tested?
12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
How many people
60 participants
Where
1 siteRussia
Study dates
11 Nov 2019to 28 Oct 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: childhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group

Who may be able to join

  • radiation and chemotherapy for cranial and craniospinal tumors in childhood or adolescence
  • completion of the therapy at least one year before enrollment
  • signed informed consent
  • there were three separate types of informed consent - for adults, for minors and for their parents
  • minors were signing informed consent in the presence of their parents.

Who cannot join

  • standard contraindications to exercise testing
  • anemia, pregnancy
  • psychiatric disease
  • alcohol or drug abuse
  • active malignancy
  • acute infection

Trial locations and contacts

1 site in 1 country.

Russia1 site
  • I.M. Sechenov First Moscow State Medical University (Sechenov University)

    Moscow

Other trials in Russia

About this study

The purpose of research is to study to adverse cardiovascular disorder and risks factors in childhood cranial and craniospinal tumors survivors. In this research the investigators investigate cardiological instrumental diagnostic, such as electrocardiography, echocardiography with the determination of global longitudinal strain, cardiopulmonary exercise test, and diagnostic of endothelial function by Angioscan for the prediction of cardiovascular complications after cranial and craniospinal radiotherapy and chemotherapy.

Read the detailed description

Cardiovascular disease, after recurrence of the original cancer and development of second primary cancers, has been reported to be the leading cause of premature mortality among long-term childhood cancer survivors. Childhood cancer survivors after chemotherapy and radiotherapy for cranial and craniospinal tumors are at increased risk of transient ischemic attack, ischemic stroke. The mechanisms of vascular damage are not well understood. Preventive measures are not developed.

The purpose of my research is to study to adverse cardiovascular disorder and risks factors in childhood cranial and craniospinal tumors survivors.

Cardiovascular risk factors monitoring and modification, development of nursing and follow-up guides of adult patients may improve outcomes in these patients after treatment for cranial and craniospinal tumors in childhood. Attempts to develop more individualized risk prediction for cardiovascular disease may help refine surveillance and counseling in the future.

This was an open prospective observational study. 68 people were enrolled in the study: 48 childhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group, and 20 healthy people formed the control group.

Criteria of inclusion to the main group were: age 16-40 years, radiation and chemotherapy for cranial and craniospinal tumors in childhood or adolescence, completion of the therapy at least one year before enrollment, signed informed consent. There were three separate types of informed consent - for adults, for minors and for their parents. Minors were signing informed consent in the presence of their parents.

Criteria of inclusion to the control group for healthy volunteers were demographics comparable to the main group.

Criteria of exclusion were: standard contraindications to exercise testing, anemia, pregnancy, psychiatric disease, alcohol or drug abuse, active malignancy, acute infection.

The study has been approved by the local ethics committee. At baseline, all patients underwent comprehensive evaluation including collection of medical history, complete physical exam, 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis. Additional carotid duplex scanning was performed in patients after craniospinal radiation therapy.

Echocardiography Left ventricular (LV) systolic and diastolic function, cardiac chamber volumes, valve function and systolic pulmonary artery pressure were evaluated using conventional transthoracic 2D-echocardiography (Dimension/Vivid 7 PRO, General Electric Medical System, Norway) according to current guidelines. Left ventricle (LV) end diastolic volume (LVEDV), end systolic volume (LVESV) and ejection fraction (LVEF) were measured with the modified Simpson method.

Cardiopulmonary exercise testing CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance. The researchers evaluated VO2 peak (highest oxygen uptake attained during exercise) and METs as its derivative, percentage from predicted VO2 peak (based on age, sex, height, and weight), anaerobic threshold (AT, defined by the V-slope method as the level of oxygen uptake at the moment of dislinear rise in minute ventilation and CO2 output relative to VO2, reflecting the shift to anaerobic metabolism and bicarbonate buffering of increased lactic acid), O2 pulse (VO2 peak/peak heart rate), ventilatory equivalent for carbon dioxide (VE/VCO2 slope), end-tidal CO2 pressure at rest and at peak exercise (PetCO2 rest and PetCO2 peak). Patient's effort was considered substantial if the self-reported number using a 1-10 modified Borg scale was ≥ 7 points and respiratory exchange ratio (RER, defined as VCO2/VO2 ratio) was ≥1.0.

Endothelial function assessment Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. The amount of light transmitted to the finger directly depends on the alterations in its blood flow. The signal obtained during PPG is displayed as a digital volume pulse (DVP) waveform. This wave usually demonstrates two deflections: an early systolic peak (a), reflecting a direct pressure wave propagation from the left ventricle to the finger, and the diastolic peak (b), that reflects backward pressure wave propagation to the aorta. The time between these two peaks (peak-to-peak time, PPT) is proportional to the subject's height. We measured large artery stiffness index (SI, a ratio between the length of aorta calculated automatically based on height to PPT), reflection index of small resistive arteries (RI, calculated as b/a x 100%), augmentation index (AI, defined as the ratio between late and early systolic pulse wave peaks, expressed as percent from the pulse pressure) and augmentation index normalized for pulse rate of 75 beats per minute (AIp75%) with regard to the fact that the heart rate has a major impact on the augmentation of pulse pressure. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH) representing the magnitude of limb reperfusion after a brief period of brachial artery occlusion. The probe was performed in the morning hours in supine position after 15 minutes of rest in a comfortable quiet warm environment according to a standardized protocol on subject preparation (fasting state, restriction of moderate-to-high physical activity, nicotine, alcohol, caffeine or other vasoactive drugs 24 hours before the probe).

Statistical analysis Microsoft Excel spreadsheet application was used for data storage and preparation for future analysis. Statistical analysis was performed using Prism 9.2.0 software. Python software was applied for multiple logistic regression models. The continuous data were expressed as a mean value (M) ± standard deviation (SD) with a 95% confidence interval (CI). Categorical variables were presented in absolute numbers and percentage and computed by using two-tailed Fischer's exact test. Normality of distribution for quantitative variables was tested using Anderson-Darling test as the first step and using Student t-test or Mann-Whitney U-test as the second step. Normality of distribution was initially evaluated as well before correlation analysis with a Pearson coefficient for normal data and with a Spearmen coefficient for non-normal data. Multiple regression models were performed considering multiple testing of hypotheses. The results of the study were presented as histograms with pairwise comparison of correlation matrices. P-value <0.05 was considered significant.

Being tested
12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
Keywords
brain tumors in children, risk of cardiovascular disease, radiation therapy, dyslipidemia, endothelial dysfunction, cardiopulmonary testing
Medical subject headings
Central Nervous System Neoplasms, Dyslipidemias

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysisDiagnostic test

    Echocardiography - standart protocol. Pulse wave characteristics were obtained using finger photopletysmography (PPG) (Angioscan-01, AngioScan-Electronics) from an infrared light sensor. Endothelial function was also evaluated using occlusion index and shear rate during post-occlusive reactive hyperemia (PORH). CPET was conducted on a treadmill (Intertrack 8100, Schiller, Switzerland) with a breath-by-breath algorithm of gas exchange analysis (Cardiovit CS-200 Ergo-Spiro, Schiller, Switzerland), using Bruce, modified Bruce or Naughton protocols depending on the level of physical tolerance.

Study groups in NCT05641636
Study groupRoleWhat they receive
childhood cancer survivors - the main groupchildhood cancer survivals after complex management of cranial and craniospinal tumors formed the main group
Receives: Diagnostic Test: 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis
the control grouphealthy people formed the control group
Receives: Diagnostic Test: 12-lead ECG, hormone and lipid blood tests, echocardiography (Echo-CG), cardiopulmonary exercise testing (CPET) and pulse wave analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dyslipidemia

    change сoncentration of total cholesterol >5 mmol/l, change сoncentration of LDL > 3 mmol/l, сoncentration of HDL <1,2 mmol/l, change сoncentration of TG >1,7 mmol/

    Measured: At baseline and through study completion of 1 year

  2. endotelian dysfunction

    change in endothelial function by Angioscan

    Measured: At baseline and through study completion of 1 year

  3. change in exercise tolerance

    change anaerobic threshold<14,0 ml/kg/min

    Measured: At baseline and through study completion of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Dec 2022
  2. Study start11 Nov 2019
  3. Primary completion30 Dec 2021
  4. Study completion28 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05641636
Sponsor's protocol ID
A-3011
Status last verified
Nov 2022
First submitted
27 Nov 2022
Last updated
7 Dec 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Tumors of the Central Nervous System and Childhood Cancer Survivors, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dyslipidemia (time frame: At baseline and through study completion of 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in